Brazil’s Anvisa defines requirements for requests for emergency use of vaccines

ANVISA, Audit, blogs, Brazil, clinical, compliance, COVID-19, drug, Health Authority Meeting, Latin America, Local Representation, Markets, News, Pharmaceuticals and Biologics, Preventative Measures, public health emergency, Quality, Regulatory Strategy, regulatory support, vaccine / By

A guide prepared by Anvisa provides guidance to development companies on procedures for emergency use authorization of Covid-19 vaccines.

Brazil’s Anvisa is approved for Pharmaceutical Inspection Co-operation Scheme – PIC/S

ANVISA, Audit, blogs, Brazil, compliance, COVID-19, drug, Health Authority Meeting, IVD, Latin America, Markets, Medical Devices, Pharmaceuticals and Biologics, Preventative Measures, public health emergency, Quality, Regulatory / By

Brazil’s ANVISA has completed the process of joining the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The Agency will become the 54th member of the international pharmaceutical inspection initiative.

Registration Of COVID-19 Rapid Tests with Brazil’s Anvisa- Required Documents

ANVISA, Audit, blogs, Brazil, compliance, COVID-19, drug, Health Authority Meeting, IVD, Latin America, Markets, Medical Devices, Pharmaceuticals and Biologics, Preventative Measures, public health emergency, Quality, Regulatory / By

Anvisa published the Resolution (RDC 348/2020) to speed up the evaluation of new products for detection of the new coronavirus (SARSCoV-2). Check out GRP’s blog on all the required documents necessary to register COVID-19 rapid tests with Brazil’s Anvisa.

Useful Links

Resources

Sign up for our Newsletter

What our Clients say about Us

Thank you GRP team for registering our DMF in china. Your helped us achieve a big milestone for our company. The support and the commitment of your regulatory team have exceeded our expectations and made it easier for us to communicate with NMPA the Chinese authority. All the best !
Director of Regulatory Affairs Officer- CMC- A Large European Pharmaceutical Company based in Switzerland
We have been working with Global Regulatory Partners for 5 years and we consider them as our real partner and not as a consulting company, they had submitted 3 INDs for us with FDA successfully . The GRP team performs all IND amendments and annual reporting to FDA, we don’t have to worry about not being in compliance with FDA requirements at all.
CEO of Medium Size American Pharmaceutical Company operating in Nanotechnology based in USA
After submitting our drug application to NPMA ( Chinese FDA) , the Chinese agency requested us to conduct a local clinical study. Finding the qualified CRO for the study management in china was very challenging process because of the language barrier and the lack of understanding of GCP and ICH requirements. We finally found Global Regulatory Partners, that has a local team of professionals in regulatory and clinical affairs in china who not only conducted successfully our clinical study in china, but also helped us to understand the Chinese regulations related to our product.
CMO of Large European Pharmaceutical Company based in France and Operating in Radiopharmaceuticals
I am very impressed on how quickly Global Regulatory Affairs team was able to prepare and organize a face to face consultation meeting for our company with Anvisa in Brazil, The meeting was successful and helped us to validate and conform the regulatory strategy of our device registration in Brazil.
VP of Global Regulatory Affairs, American Based Medical device Company

Copyright ©2019 Global Regulatory Partners

Scroll to Top

Contact